

# Evermine<sup>TM</sup>50

## EES Post-marketing Study

Clinical Outcomes of World's Thinnest (50  $\mu$ m) Strut Biodegradable Polymer Coated Everolimus-Eluting Coronary Stent System in Real-World Patients

## Evermine50 EES post-marketing study design


### PROSPECTIVE, SINGLE-ARM, SINGLE-CENTER, POST-MARKETING, REAL-WORLD STUDY

- From March 2017 to April 2018 this study enrolled 251 patients with Evermine50 EES for managing CAD from a single-centre in India.
- Inclusion Criteria:** Patients aged above 18 years with stable CAD or acute coronary syndrome, having *de novo* native coronary artery lesions (lengths <44 mm) and/or in-stent restenosis with a reference vessel diameter of 2.0 mm to 4.5 mm, and compatible to Evermine50 EES implantation
- Patients with mean age of  $58.20 \pm 9.92$  years and 76.9% males with at least one *de novo* coronary artery lesion included:
  - DM- 48.6%
  - HTN- 45.4%
  - STEMI- 48.2%
  - UA- 10.4%
- Primary Endpoints:** MACE, composite of cardiac death, MI attributed to the target vessel, and CD-TLR at 6-month follow-up after the index procedure
- Additional Endpoints:** Procedural success (successful stent placement at the desired position without any death, TVMI, or repeat revascularization of target lesion), device success (achievement of a final residual diameter stenosis < 30%) and ST (ARC criteria)

### PRIMARY ENDPOINT


Evermine50 EES demonstrated a 0.8% MACE rate at 6-month CAD population

The cumulative MACE-free survival, determined by the Kaplan–Meier method, was 99.2%



# Clinical Outcomes


## KEY CLINICAL ENDPOINTS AT 6-MONTH:



## MACE RATE:



## KEY OUTCOMES:



The outcomes of the real-world study demonstrated lower incidence of the MACE after implantation of biodegradable polymer coated thinnest (50  $\mu$ m) strut Evermine50 EES, which depicts favourable clinical safety and performance in patients with coronary artery disease



CTRI/2017/03/008173

India Copyrights © 2024 Meril Life Sciences Pvt. Ltd. All rights reserved.